PHASE II, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF HIV COGNITIVE

HIV 认知的 II 期、随机、安慰剂对照研究

• 批准号: 7951569
• 负责人: ELYSE J SINGER
• 金额: $ 3.52万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951569
• 关键词: 3-nitrotyrosine; 4 hydroxynonenal; Apoptosis; Blood; CCL2 gene; Ceramides; Cerebrospinal Fluid; Clinical Research; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; HIV-1; Immunologic Markers; Impaired cognition; Individual; Institution; Minocycline; Monocyte Chemoattractant Proteins; Oxidative Stress; Phase; Proteins; RNA; Research; Research Personnel; Resources; Source; Sphingomyelins; United States National Institutes of Health; functional disability; improved; randomized placebo controlled trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Objective " To examine whether minocycline treatment for 24 weeks improves HIV-associated cognitive impairment. Secondary Objectives " To examine whether minocycline treatment for 24 weeks is safe and well-tolerated in individuals with HIV-associated cognitive impairment. " To examine whether minocycline treatment for 48 weeks is safe and well-tolerated in individuals with HIV-associated cognitive impairment. " To examine whether minocycline treatment for 24 weeks improves functional impairment. " To examine whether minocycline treatment for 24 weeks decreases levels of several markers of HIV-associated cognitive impairment including, but not limited to, HIV-1 RNA; a marker of immune activation, [monocyte chemoattractant protein (MCP-1)]; a marker of apoptosis (sFas); markers of oxidative stress [ceramide, sphingomyelin, 4-hydroxynonenal (HNE), and 3-nitrotyrosine [3-NT] modified proteins] in blood and cerebrospinal fluid (CSF).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 具体目的： 主要目标 “要检查米诺环素治疗24周是否可以改善与HIV相关的认知障碍。 次要目标 “要检查与艾滋病毒相关的认知障碍的患者，米诺环素治疗24周是否安全且耐受性良好。 “要检查米诺环素治疗48周是否在患有艾滋病毒相关的认知障碍的个体中安全且耐受性良好。 “要检查米诺环素治疗24周是否可以改善功能障碍。 " To examine whether minocycline treatment for 24 weeks decreases levels of several markers of HIV-associated cognitive impairment including, but not limited to, HIV-1 RNA; a marker of immune activation, [monocyte chemoattractant protein (MCP-1)]; a marker of apoptosis (sFas); markers of oxidative stress [ceramide, sphingomyelin, 4-hydroxynonenal血液和脑脊液（CSF）中的（HNE）和3-硝基酪氨酸[3-NT]改性蛋白。